same insulin that applied as of July 1, 2006, increased by not more than the rate by which the medical care component of the consumer price index for all urban consumers (U.S. city average) increased between September 30, 2020, and the date on which the certification is submitted. (B) Subsequent certification For plan year 2023 and each plan year thereafter, a manufacturer of insulin who previously submitted a certification under clause (i) or (ii) of subparagraph (A) is considered certified under this subsection for the applicable plan year if such manufacturer submits, not later than September 30 of the calendar year that is 2 years prior to the applicable plan year, a certification that the manufacturer did not increase the list price for insulin previously certified under clause (i) or (ii) of subparagraph (A), by more than the rate by which the medical care component of the consumer price index for all urban consumers (U.S. city average) increased since the initial certification under such clause (i) or (ii). (3) Special rule for certain insulin (A) In general In the case of a manufacturer of insulin that did not manufacture a particular insulin in 2006, such manufacturer may be certified under this subsection with respect to such insulin by submitting information under paragraph (2)(A) certifying that the list price of such insulin is no greater than the weighted average list price, in 2006, of, as applicable— (i) (I) all short-acting insulins